Cancer drug start-up Peloton raises $18M

Peloton Therapeutics, a Dallas, Texas-based early-stage small-molecule cancer drug company, has come out of stealth mode. It has announced that it raised $18 million in a series A financing for development on three in-licensed programmes from the University of Texas Southwestern Medical Center. This follows an $11 million grant from cancer research funds provided by the state of Texas.

The venture capital firm, The Column Group, led the round, and was joined by Remeditex Ventures and individual investor Peter...